Published in Vaccine Weekly, June 22nd, 1998
Researchers from Germany's Max-Planck Institute for Infection Biology found that certain antigens with the pore-forming sulfhydryl-activated cytolysin Hly may enhance CD8 T cell stimulation.
Bacillus Calmette-Guerin (BCG), the only vaccine available for the prevention of tuberculosis, has shown an efficacy ranging from 0 percent to 80 percent in field trials.
"BCG should be improved, e.g., by genetic engineering to provide a vaccine for better TB...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly